MARKET

GHRS

GHRS

Gh Research Plc
NASDAQ
19.56
+0.30
+1.56%
After Hours: 19.56 0 0.00% 16:15 11/10 EST
OPEN
19.04
PREV CLOSE
19.26
HIGH
19.85
LOW
18.83
VOLUME
108.74K
TURNOVER
--
52 WEEK HIGH
31.44
52 WEEK LOW
12.04
MARKET CAP
1.34B
P/E (TTM)
-19.8116
1D
5D
1M
3M
1Y
5Y
1D
RBC Capital Keeps Their Buy Rating on GH Research (GHRS)
TipRanks · 1d ago
H.C. Wainwright Reaffirms Their Buy Rating on GH Research (GHRS)
TipRanks · 1d ago
Weekly Report: what happened at GHRS last week (1102-1106)?
Weekly Report · 1d ago
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 5d ago
COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission
Seeking Alpha · 11/03 13:41
Usona psilocybin filing has implications for Compass, Definium, says Canaccord
TipRanks · 11/02 20:15
Weekly Report: what happened at GHRS last week (1026-1030)?
Weekly Report · 11/02 09:20
Weekly Report: what happened at GHRS last week (1019-1023)?
Weekly Report · 10/26 09:20
More
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.

Webull offers GH Research PLC stock information, including NASDAQ: GHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GHRS stock methods without spending real money on the virtual paper trading platform.